LEADER 02971nam 2200505 450 001 9910717367103321 005 20221104070223.0 035 $a(CKB)3790000000310888 035 $a(NjHacI)993790000000310888 035 $a(OCoLC)862321793$z(OCoLC)878436113$z(OCoLC)1117874724 035 $a(EXLCZ)993790000000310888 100 $a20221104d2013 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAssessment of alternative treatment strategies for chronic genotype 1 hepatitis C /$fPaul G. Barnett [and nine others] editors 210 1$aWashington (DC) :$cDepartment of Veterans Affairs,$d[2013] 210 4$dİ2013 215 $a1 online resource (iii, 37 pages) $cillustrations 300 $a"Evidence-based synthesis program." 300 $a"March 2013." 320 $aIncludes bibliographical references. 330 3 $aThere is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available triple combination therapies that include directly acting antivirals (DAA) along with recently developed patient genotyping (IL-28B) which is predictive of HCV treatment response. Chronic GT1 HCV infections have been historically difficult to treat, with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified. 606 $aAntiviral agents 606 $aHepatitis C virus 607 $aUnited States$2fast 608 $aTechnical reports.$2lcgft 615 0$aAntiviral agents. 615 0$aHepatitis C virus. 676 $a616.925061 700 $aGoldhaber-Fiebert$b Jeremy D.$01412326 702 $aBarnett$b Paul G. 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aWest Los Angeles VA Medical Center.$bEvidence-Based Synthesis Program Center. 712 02$aVA Health Economics Resource Center (U.S.) 712 02$aQuality Enhancement Research Initiative (U.S.) 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910717367103321 996 $aAssessment of alternative treatment strategies for chronic genotype 1 hepatitis C$93505467 997 $aUNINA